[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"enterobacteria-non-susceptible-to-carbapenem-carrier\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:enterobacteria-non-susceptible-to-carbapenem-carrier":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100623433","predictive-score-in-patients-with-hematological-malignancies-colonized-by-multidrug-resistant-enterobacteriaceae-100623433",false,"NCT07396571","Predictive Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae","Development of a Predictive Infection Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae","SCREEN-IN","Inclusion criteria\n\n* Patients admitted to Hematology departments with hematological diseases, including: myelodysplastic syndrome, acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, chronic lymphocytic leukemia, chronic myeloproliferative leukemias, lymphomas, or other hematological disorders.\n* Patients scheduled to receive treatment for their underlying hematological disease, including myeloablative\u002Fcytotoxic chemotherapy, conditioning chemotherapy for hematopoietic stem cell transplantation (autologous, allogeneic, or other types), lymphodepleting chemotherapy for CAR-T cell therapy, and\u002For other treatments expected to induce neutropenia.\n* Patients expected to develop neutropenia (neutrophil count \\\u003C 0.5 \\\\times 10\\^9\u002FL, or \\\u003C 1.0 \\\\times 10\\^9\u002FL when predicted to fall below 0.5 \\\\times 10\\^9\u002FL within the next 48 hours) in the coming days.\n* Those who have signed the informed consent form.\n* Participation in another study is permitted, provided it is observational and does not influence the potential colonization status.\n\nExclusion criteria\n\n* Psychiatric disorder or inability to understand or follow the protocol instructions.\n* Terminally ill patients or those with an estimated life expectancy of less than 30 days.\n* Previous enrollment in the study.\n* Known prior colonization by ESBL-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE).\n* Physician's discretion: The patient's attending physician prefers not to include the patient in the study.","ALL","18 Years",{"count":20,"type":21},535,"ESTIMATED","OBSERVATIONAL","The goals of this observational study are to identify risk factors for ESBL-producing Enterobacterales and carbapenemase-producing Enterobacterales (CPE) colonization in oncohematological patients with severe neutropenia, and to develop and validate a predictive model of infection caused by ESBL-producing Enterobacterales and CPE in patients previously colonized by the same bacteria.\n\nThe main questions the study aims to answer are:\n\n* What are the risk factors for ESBL-producing Enterobacterales and CPE colonization in patients with severe neutropenia?\n* Can a predictive model be developed to accurately predict infections in the colonized patients?\n\nStudy Design \\& Participants: Participants will be screened after receiving neutropenia-inducing treatment (e.g., chemotherapy, chimeric antigen receptor T-cell (CAR-T) therapy, or others). A baseline rectal swab will be collected to assess initial colonization status, followed by weekly swabs throughout the duration of neutropenia. Patients will be followed for 90 days from initial screening, during which the study team will record any infections, with an additional 30-day follow-up period. All hospitalization data will be recorded.",[25,26,27,28,29],"Hemato-oncologic Patients","Colonization","Neutropenia","Enterobacteria Non Susceptible to Carbapenem Carrier","ESBL-producing Enterobacteriaceae Infections","NOT_YET_RECRUITING","2026-02-27",{"date":33,"type":34},"2026-03-02","ACTUAL",{"date":36,"type":21},"2026-02",{"date":38,"type":21},"2028-12",{"name":40,"class":41},"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","OTHER",15]